Ifomid M 1/200 

Ifomid M 1/200 is a prescription medication used to treat certain types of cancer, including lymphoma, leukemia, and soft tissue sarcoma. It is a combination of ifosfamide and mesna in a single injection.

Composition:

• Ifosfamide (ifosfamide) 100mg/2ml
• Mesna (mesna) 200mg/2ml

Mechanism of Action:

Ifosfamide works by:

1. Inhibiting the activity of DNA repair enzymes, which can help to:
   • Damage the DNA of cancer cells
   • Prevent cancer cells from repairing damaged DNA
2. Inhibiting the activity of topoisomerase II, which can help to:
   • Prevent cancer cells from replicating their DNA
   • Induce apoptosis (cell death) in cancer cells

Mesna works by:

1. Inactivating the toxic metabolites of ifosfamide, which can help to:
   • Reduce the risk of hemorrhagic cystitis (a type of bladder damage)
   • Reduce the risk of other side effects associated with ifosfamide

Indications:

Ifomid M 1/200 is approved for the treatment of:

• Lymphoma (non-Hodgkin’s lymphoma and Hodgkin’s lymphoma)
• Leukemia (acute myeloid leukemia and chronic myeloid leukemia)
• Soft tissue sarcoma (e.g., osteosarcoma, soft tissue sarcoma)

Dosage:

The recommended dosage of Ifomid M 1/200 is:

• 100mg/2ml as an intravenous injection every 3-4 weeks
• The recommended duration of treatment is until disease progression or unacceptable toxicity occurs

Side Effects:

Common side effects of Ifomid M 1/200 include:

1. Nausea
2. Vomiting
3. Diarrhea
4. Abdominal pain
5. Fatigue
6. Headache
7. Muscle pain
8. Bone marrow suppression (anemia, neutropenia, thrombocytopenia)
9. Hemorrhagic cystitis (bladder damage)
10. Increased risk of infections

Recommendation:

Ifomid M 1/200 is recommended for patients with lymphoma, leukemia, or soft tissue sarcoma who have not responded to other treatments.

Important Note:

• Patients taking Ifomid M 1/200 should be closely monitored for signs of cardiac problems, such as heart failure or arrhythmias.
• Patients taking Ifomid M 1/200 should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase the risk of bleeding.
• Pregnant or breastfeeding women should not use Ifomid M 1/200, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Ifomid M 1/200 and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of heart problems or liver disease should be closely monitored while taking Ifomid M 1/200.
• Patients with a history of severe allergic reactions should be closely monitored while taking Ifomid M 1/200.

Contraindications:

• Patients who are allergic to ifosfamide or mesna or any other component of Ifomid M 1/200 should not use it.
• Patients who are pregnant or breastfeeding should not use Ifomid M 1/200.
• Patients with severe liver disease or severe kidney disease should not use Ifomid M 1/200.